A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.

Thuluva, Subhash; Gunneri, SubbaReddy; Turaga, Kishore; Mogulla, Rammohan Reddy; Yerroju, Vijay; Peta, Kalyankumar; Suneetha, Pothakamuri Venkata; Matur, Ramesh V

Thuluva, Subhash; Gunneri, SubbaReddy; Turaga, Kishore; Mogulla, Rammohan Reddy; Yerroju, Vijay; Peta, Kalyankumar; Suneetha, Pothakamuri Venkata; Matur, Ramesh V.

Thuluva S; Biological E Limited, 18/1&3, Azamabad, Hyderabad, 500 020, Telangana, India.
Gunneri S; Biological E Limited, 18/1&3, Azamabad, Hyderabad, 500 020, Telangana, India.
Turaga K; Biological E Limited, 18/1&3, Azamabad, Hyderabad, 500 020, Telangana, India.
Mogulla RR; Biological E Limited, 18/1&3, Azamabad, Hyderabad, 500 020, Telangana, India.
Yerroju V; Biological E Limited, 18/1&3, Azamabad, Hyderabad, 500 020, Telangana, India.
Peta K; Biological E Limited, 18/1&3, Azamabad, Hyderabad, 500 020, Telangana, India.
Suneetha PV; Biological E Limited, 18/1&3, Azamabad, Hyderabad, 500 020, Telangana, India.
Matur RV; Biological E Limited, 18/1&3, Azamabad, Hyderabad, 500 020, Telangana, India.

Contemp Clin Trials Commun ; 36: 101232, 2023 Dec.

Article en En | MEDLINE | ID: mdl-38058513